Please use this identifier to cite or link to this item: http://repo.knmu.edu.ua/handle/123456789/25123
Title: Novel score-based decision approach in chronic myeloid leukemia patients after acute toxic Imatinib-induced liver injury
Authors: Lopina, Nataliia
Dmytrenko, Iryna
Hamov, Dmytro
Lopin, Dmytro
Dyagil, Iryna
Keywords: acute toxic hepatitis
acute liver failure
chronic myeloid leukemia,
chronic myeloid leukemia second-line therapy
tyrosine kinase inhibitors
imatinib
druginduced liver disease
Issue Date: 2019
Citation: Novel score-based decision approach in chronic myeloid leukemia patients after acute toxic Imatinib-induced liver injury / N. Lopina, I. Dmytrenko, D. Hamov, D. Lopin, I. Dyagil // Cureus. ‒ 2019. ‒ Vol. 11, N 4. ‒ e4411. ‒ DOI: 10.7759/cureus.4411.
Abstract: The tyrosine kinase inhibitor (TKI) imatinib in rare cases can cause acute toxic hepatitis, hepatic failure, and death. Currently, the choice of further chronic myeloid leukemia (CML) therapy in patients after acute hepatotoxicity is still a difficult question, which requires a complex individual approach based on the clinical guidelines of adverse event management. Data about the further follow-up strategy approach in patients with CML after acute toxic imatinib-induced liver injury are of concern, and at times controversial. In addition, one of the questions is about the necessity and safety of the imatinib therapy resumption after acute hepatotoxicity. In some publications, imatinib resumption without the recurrence of hepatotoxicity has been discussed; in others, imatinib resumption with the recurrence of imatinib hepatotoxicity has been mentioned.
URI: http://repo.knmu.edu.ua/handle/123456789/25123
Appears in Collections:Наукові праці. Кафедра внутрішньої медицини № 3 та ендокринології

Files in This Item:
File Description SizeFormat 
Imatinib induced Liver Injury.pdf341,53 kBAdobe PDFView/Open


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.